» Articles » PMID: 9472019

4E-BP1, a Repressor of MRNA Translation, is Phosphorylated and Inactivated by the Akt(PKB) Signaling Pathway

Overview
Journal Genes Dev
Specialty Molecular Biology
Date 1998 Mar 21
PMID 9472019
Citations 354
Authors
Affiliations
Soon will be listed here.
Abstract

Growth factors and hormones activate protein translation by phosphorylation and inactivation of the translational repressors, the eIF4E-binding proteins (4E-BPs), through a wortmannin- and rapamycin-sensitive signaling pathway. The mechanism by which signals emanating from extracellular signals lead to phosphorylation of 4E-BPs is not well understood. Here we demonstrate that the activity of the serine/threonine kinase Akt/PKB is required in a signaling cascade that leads to phosphorylation and inactivation of 4E-BP1. PI 3-kinase elicits the phosphorylation of 4E-BP1 in a wortmannin- and rapamycin-sensitive manner, whereas activated Akt-mediated phosphorylation of 4E-BP1 is wortmannin resistant but rapamycin sensitive. A dominant negative mutant of Akt blocks insulin-mediated phosphorylation of 4E-BP1, indicating that Akt is required for the in vivo phosphorylation of 4E-BP1. Importantly, an activated Akt induces phosphorylation of 4E-BP1 on the same sites that are phosphorylated upon serum stimulation. Similar to what has been observed with serum and growth factors, phosphorylation of 4E-BP1 by Akt inhibits the interaction between 4E-BP1 and eIF-4E. Furthermore, phosphorylation of 4E-BP1 by Akt requires the activity of FRAP/mTOR. FRAP/mTOR may lie downstream of Akt in this signaling cascade. These results demonstrate that the PI 3-kinase-Akt signaling pathway, in concert with FRAP/mTOR, induces the phosphorylation of 4E-BP1.

Citing Articles

AKT kinases as therapeutic targets.

Hassan D, Menges C, Testa J, Bellacosa A J Exp Clin Cancer Res. 2024; 43(1):313.

PMID: 39614261 PMC: 11606119. DOI: 10.1186/s13046-024-03207-4.


PPM1G dephosphorylates eIF4E in control of mRNA translation and cell proliferation.

Wang P, Li Z, Kim S, Xu H, Huang H, Yang C Life Sci Alliance. 2024; 7(10).

PMID: 39111820 PMC: 11306785. DOI: 10.26508/lsa.202402755.


Potential roles of UCH family deubiquitinases in tumorigenesis and chemical inhibitors developed against them.

Xu Z, Zhang N, Shi L Am J Cancer Res. 2024; 14(6):2666-2694.

PMID: 39005671 PMC: 11236784. DOI: 10.62347/OEGE2648.


Interplay between WNT/PI3K-mTOR axis and the microbiota in APC-driven colorectal carcinogenesis: data from a pilot study and possible implications for CRC prevention.

Di Paola F, Alquati C, Conti G, Calafato G, Turroni S, DAmico F J Transl Med. 2024; 22(1):631.

PMID: 38970018 PMC: 11227240. DOI: 10.1186/s12967-024-05305-5.


eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

Boyer J, Sharma M, Dorso M, Mai N, Amor C, Reiter J bioRxiv. 2024; .

PMID: 38766126 PMC: 11100762. DOI: 10.1101/2024.05.08.593195.


References
1.
Franke T, Kaplan D, Cantley L . PI3K: downstream AKTion blocks apoptosis. Cell. 1997; 88(4):435-7. DOI: 10.1016/s0092-8674(00)81883-8. View

2.
Marte B, Downward J . PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci. 1997; 22(9):355-8. DOI: 10.1016/s0968-0004(97)01097-9. View

3.
Edery I, Altmann M, Sonenberg N . High-level synthesis in Escherichia coli of functional cap-binding eukaryotic initiation factor eIF-4E and affinity purification using a simplified cap-analog resin. Gene. 1988; 74(2):517-25. DOI: 10.1016/0378-1119(88)90184-9. View

4.
Montine K, Sonenberg N . Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature. 1990; 345(6275):544-7. DOI: 10.1038/345544a0. View

5.
Evan G, Wyllie A, GILBERT C, Littlewood T, Land H, Brooks M . Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992; 69(1):119-28. DOI: 10.1016/0092-8674(92)90123-t. View